Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-04-05
2011-04-05
Parkin, Jeffrey S (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S208100
Reexamination Certificate
active
07919101
ABSTRACT:
Provided herein are pharmaceutical compositions for the prophylactic and therapeutic treatment of HIV comprising combinations of HIV fusion/entry inhibitors that exhibit synergistic effect, including T-20 (enfuvirtide), T-1249, T-1144, C34, and sifuvirtide. Also disclosed are methods of treating HIV infection by administering such compositions.
REFERENCES:
patent: 2004/0062767 (2004-04-01), Olson et al.
patent: 2007/0179278 (2007-08-01), Dwyer et al.
Gustchina, E., et al., 2007, A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains, J. Virol. 81(23):12946-12953.
Zwick, M. B., et al., 2005, Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1, J. Virol. 79(2):1252-1261.
Zwick, M. B., et al., 2001, Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies, J. Virol. 75(24):12198-12208.
Jiang, S., et al., 2004, N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion, Antimicrob. Agents Chemother. 48(11):4349-4359.
Root, M. J., and D. H.Hamer, 2003, Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein, Proc. Natl. Acad. Sci. USA 100(9):5016-5021.
Pan, C., et al. 2009. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide-sensitive and -resistant HIV type 1 strains. J. Virol. 83(16):7862-7872.
Tremblay, C. 2004. Effects of HIV-1 entry inhibitors in combination. Curr. Pharm. Des. 10:1861-1865.
Buchacher et al. “Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.” AIDS Res Hum Retroviruses. vol. 10, No. 4, pp. 359-369, 1994.
Chan et al. “Core structure of gp41 from the HIV envelope glycoprotein.” Cell, vol. 89, 263-273, 1997.
Chan et al. “Evidence that prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target.” Proc. Natl. Acad. Scien. USA, col. 95, pp. 15613-15617, 1998.
Chan et al. “HIV entry and its inhibition.” Cell, vol. 93, 681-684, 1998.
Chinnadurai et al. “Human Immunodeficiency Virus Type 1 Variants Resistant to First and Second Version Fusion Inhibitors and Cytopathic in Ex Vivo Human Lymphoid Tissue.” Journal of Virology, p. 6563-6572, vol. 81, No. 12, 2007.
Debnath et al. “Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1.” J Med Chem. 42(17):3203-9, 1999.
Dwyer et al. “Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.” PNAS 12772-17222, vol. 104, No. 31, 2007.
Eckert et al. “Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues.” J. Mol. Biol. 284:859-865, 1998.
Eckert et al. “Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket.” Cell. vol. 99, 103-115, 1999.
Eckert et al. “Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.” PNAS, vol. 98, No. 20, 11187-11192, 2001.
Eggink et al. “Selection of T1249-Resistant Human Immunodeficiency Virus Type 1 Variants.” Journal of Virology, p. 6678-6688, vol. 82, No. 13, 2008.
Eron et al. “Short-term Safety and Antiretroviral Activity of T-1249, a Second-Generation Fusion Inhibitor of HIV.” The Journal of Infectious Diseases, 189, 1075-1083, 2004.
He et al. “Indentification of a Critical Motif for the Human Immunodeficiency Virus Type 1 (HIV-1) gp41 Core Structure: Implications for Designing Novel Anti-HIV Fusion Inhibitors.” Journal of Virology, p. 6349-6358, vol. 82, No. 13, 2008.
Hogg et al. “Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy.” AIDS. 1998; 12:279-284.
Jiang et al. “HIV-1 inhibition by a peptide.” Nature, vol. 365, 1993.
Jiang et al. “A Conformation-Specific Monoclonal Antibody Reacting with Fusion-Active gp41 from the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein.” Journal of Virology, p. 10213-10217, vol. 72, No. 12, 1998.
Jiang et al. “A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody.” J. Virol. Methods 80, 1999, 85-96.
Jiang et al. “A convenient cell fusion assay for rapid screening for HIV entry inhibitors.” Proc. SPIE. 2000; 3926:212-219.
Jiang et al. “N-Substituted Pyrrole Derivatives as Novel Human Immunodeficiency Virus Type 1 Entry Inhibitors that Interfere with the gp41 Six-Helix Bundle Formation and Block Virus Fusion.” Antimicrobial Agents and Chemotherapy, p. 4349-4359, vol. 48, No. 11, 2004.
Kilby et al. “Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.” Nature Med. 1998; 4:1302-1307.
Kilby et al. “The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.” AIDS Res. Hum. Retroviruses. 2002; 18:685-693.
Kilby et al. “Novel therapies based on mechanisms of HIV-1 cell entry.” N. Engl. J Med. 2003; 348:2228-2238.
Lalezari et al. “T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen,” J Infect. Dis. 2005; 191:1155-1163.
Lawless et al. “HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.” Biochemistry. Oct. 22, 1996;35(42):13697-708.
Liu et al. “Determination of the HIV-1 gp41 postfusion conformation modeled by synthetic peptides: applicable for identification of the HIV-1 fusion inhibitors.” Peptide. 2003; 24:1303-1313.
Liu et al. “Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.” J. Biol. Chem. 2005; 280:11259-11273.
Liu et al. “HIV gp41 C-terminal heptad repeat contains multifunctional domains: relation to mechanisms of action of anti-HIV peptides.” J. Biol. Chem. 2007; 282:9612-9620.
Liu et al. “HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds.” Curr. Pharm. Des. 2007; 13:143-162.
Louis et al. “Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity.” J. Biol. Chem. 2001; 276:29485-29489.
Louis et al. “Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion.” J Biol. Chem. 2003; 278:20278-20285.
Lu et al. “A trimeric structural domain of the HIV-1 transmembrane glycoprotein.” Nat. Struct. Biol. 1995; 2:1075-1082.
Menzo et al. “Genotype and Phenotype Patterns of Human Immunodeficiency Virus Type 1 Resistance to Enfuvirtide during Long-Term Treatment.” Antimicrobial Agents and Chemotherapy, p. 3253-3259, vol. 48, No. 9, 2004.
Miller et al. “A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.” PNAS, vol. 102, No. 41, 14759-14764, 2005.
Moore et al. “The entry of entry inhibitors: A fusion of scie
Jiang Shibo
Pan Chungen
Bergman Michelle Glasky
Cullman Louis C.
K&L Gates LLP
New York Blood Center
Parkin Jeffrey S
LandOfFree
Highly potent synergistic combinations of human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Highly potent synergistic combinations of human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Highly potent synergistic combinations of human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2650091